Pressure BioSciences Inc. PBIO Archives - Page 21 of 22

TuesdayDec 18, 2007 10:16 am

Dutton Associates Maintains “Speculative Buy” Rating and $10.00 Price Target for Pressure BioSciences Inc. (PBIO)

Dutton Associates announced today that it has updated its coverage of Pressure BioSciences and that it is reiterating its “Strong Speculative Buy” Rating and $10.00 Price Target. Dutton’s Senior Analyst, Mr. Denise T. Resnik, M.S., completed the 17-page report. The research firm stated, “We are reiterating our rating of Pressure BioSciences Inc. as a Strong Speculative Buy and our 12-month price target of $10.00 per share. The Company has developed a unique and superior technology for the preparation of biological laboratory samples and is in the early stages of commercialization of its product platform. We expect that the shares will…

ThursdayDec 13, 2007 5:34 am

Pressure BioSciences, Inc. (PBIO) ProteoSolve-LRS Technology Plays Significant Role in Identyfing Potential Biomarkers in Cancer

Pressure BioSciences announced this morning that the scientists at New York University reported that the Company's award winning technology, the ProteoSolve-LRS, had a large part in identifying potential biomarkers in breast and colon cancer tissue. The results were presented at the LC-MS Course and Symposium, Robinson College, Cambridge, England by Dr. Paul Pevsner of the NYU School of Medicine Department of Pharmacology. The ProteoSolve-LRS was recently released by the company to provide a solution for the detergent-free removal of proteins from lipid-rich tissues as well as other tissues. The study of proteins could lead to a better understanding of many…

WednesdayDec 12, 2007 6:28 pm

Pressure BioSciences Inc. (PBIO) is “On Alert”

Pressure BioSciences Inc. is a life sciences company we have followed for much of this year through our relationship with the Red Chip Conferences. Pressure BioSciences, Inc. shares were hit with an inexplicable sell off this week, which has many speculating the sell off could be due impart to investor confusion linking Pressure BioSciences, Inc. and Panacos Pharmaceuticals Inc. which neared its 52 week low after disappointing results from Panacos HIV drug candidate bevirimat. Pressure BioSciences Inc. did initially have a passive investment in Panacos Pharmaceuticals, but sold off all of its interest in the investment over six month ago,…

WednesdayDec 12, 2007 6:10 pm

Pressure Biosciences, Inc. (PBIO) Develops Barocycler NEP2320 with Advanced Features

Pressure Biosciences, Inc. (NASDAQ: PBIO) focuses on the development of a technology called Pressure Cycling Technology (PCT) which, by definition, uses rapid cycles of hydrostatic pressure between ambient and ultra high levels to control biomolecular interactions, allowing for a high degree of precision, reproducibility, convenience, speed and safety. One application for the technology is to aid researchers in understanding obesity and other diseases. The Barocycler NEP2320 is one such PCT device designed for laboratories that want improved sample preparation in genomics, proteomics, transcriptomics and metabolomics. Processing one sample at a time, the Barocycler NEP2320 uses laboratory compressed air, bottled compressed…

WednesdayDec 12, 2007 11:51 am

Pressure BioSciences, Inc. (PBIO) Recently Awarded $7 Price Target

RedChip analyst, Joe Blanksenship, MBA, awarded Pressure BioSciences a $7.00 price target and rated their stock a “Speculative Buy” following the company's Q2 2007 report. In the research report, the analyst stated, “Pressure Biosciences, Inc. continues on its path to commercialization with its pressure cycling technology (“PCT”) used in sample preparation across a broad range of life-sciences applications.” The Company reported the sale of four Barocycler NEP3229 PCT Sample Preparation Systems compared to the one sold in the same period last year. $202,127 was announced as the total revenue for the quarter, which is approximately 7x the amount from Q2 2006.…

MondayDec 10, 2007 5:46 pm

Pressure Biosciences, Inc. (PBIO) Reports Increase of Sales, Revenue, and Cash on Hand

Pressure Biosciences, Inc. (NASDAQ: PBIO) recently reported the sale of four of its Barocycler NEP3229 PCT Sample Preparation Systems. Compare that to the sale of only one system in the second quarter of last year, and you’ve got a company on the move. The company also posted $65,772 in grant revenue for the quarter ended June 30, 2007; last year it reported none. Additionally, Pressure Biosciences posted $202,127 for the second quarter of 2007, as compared to $28,783 in the same period of 2006. Cash on hand as of June 30, 2007, was about $6.8 million, up from $5.3 million…

MondayDec 10, 2007 3:24 pm

Pressure Biosciences, Inc. (PBIO) Disease-Fighting Technology Earns Award and Applause

Pressure Biosciences, Inc. (NASDAQ: PBIO), a life sciences company based in Massachusetts, researches, develops, and commercializes on sample preparation systems. The company’s cornerstone is its pressure cycling technology (PCT) that has the ability to use hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. In layman’s terms, the company’s technology opens the door to further insight into diseases such as obesity, heart disease, diabetes and certain cancers. The company’s efforts are not only contributing to technological advancement, but are also winning awards. Last month, Pressure Biosciences was awarded the 2007 North American Frost & Sullivan Award for Technology…

MondayDec 10, 2007 11:39 am

Pressure BioSciences, Inc. (PBIO) Prices Surge over 18% on Skyrocketing Volume

After Redchip’s announcement this morning that Pressure BioSciences would be a featured company in their upcoming investor conference, prices surged to reach a High-of-Day at $6.82, which is 18.2% higher than yesterday’s close. Volume also exploded reaching a 852% increase compared to the 15 day average. Dutton Associates recently issued a research note reiterating their “Strong Speculative Buy” rating and initiating price target of $10. In conclusion of the independent report, the analyst stated, “In sum, we believe that Pressure BioSciences has attained its short-term goals regarding commercialization and is well poised to continue to market its PCT systems in the…

MondayDec 10, 2007 7:25 am

Pressure BioSciences Inc. (PBIO) to be Featured at the RedChip Small-Cap Investor Conference

RedChip announced this morning that the CEOs and executive teams of 30 emerging small-cap companies will be presenting at this year’s RedChip Small-Cap Investor Conference at the Four Seasons Resort in Scottsdale, Arizona - Feb. 7, 2008, from 8 a.m. to 5 p.m. The conference is known around the nation for featuring small-cap companies who have remarkable stories to present in front of hundreds of investment bankers, fund managers, institutional and accredited investors, research analysts, and high net worth individuals. Presenters such as Pressure BioSciences will also have the opportunity to meet with RedChip’s top retail brokers, institutional brokers, and financial…

FridayDec 07, 2007 12:37 pm

Pressure Biosciences, Inc. (PBIO) Places Focus on Battling Obesity with Patented Technology

According to the U.S. Centers for Disease Control and Prevention’s (CDC) most recent statistics, obesity is the number one health threat facing Americans, killing about 400,000 people each year with medical and other costs tipping the scale near $123 billion annually. Pressure Biosciences, Inc.’s (Nasdaq: PBIO) patented technology may come in useful in fighting America’s rising killer. Pressure Biosciences’ pressure cycling technology (PCT) uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The technology has applications in genomics (the study of an organism’s hereditary information encoded in its DNA), proteomics (study of structures and functions…

Site Search

Company Search

Tag: Pressure BioSciences Inc. PBIO